Dare Bioscience Financial Results
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
- Term
- Q3 2026